drugset
drugset / Trial / NCT03814200

A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects

NCT03814200 ↗

Phase 1 Completed 14 enrolled Viatris Innovation GmbH
RandomizedCrossoverQuadruple-blindOther

Summary

The study will investigate the effect of rifampicin on the uptake and breakdown of ACT-246475 in healthy subjects

Timeline

Start
2019-01-03
Primary completion
2019-02-12
Completion
2019-02-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifampin Small molecule 600 mg Intravenous
Subject Selatogrel Small molecule 4 mg Subcutaneous

Indications

No indication recorded.